The Future of ART Regimens for HIV Is in Long-Acting Agents
Recent developments in antiretroviral therapy (ART) include longer-acting therapies that don’t require a daily oral pill and two-drug regimens that could decrease toxicity associated with standard triple-drug regimens. The approval of cabotegravir plus rilpivirine (Cabenuva) in January 2021 was the first to provide both benefits as a monthly ART injection. The approval was expanded to […]